Across TCGA pan-cancer cohorts, ZNF114 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF114 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher ZNF114 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF114 expression acts as an unfavorable survival marker.
SARC and UCEC are the cancer types where ZNF114 Mutation most reproducibly stratifies survival.